Zhong Yadi, Zhai Bing, Zeng Jing, Yang Bo, Guo Bo, Lu Xuechun
Department of Hematology, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.
Department of Endocrinology, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.
Cancer Pathog Ther. 2024 Jun 8;2(4):285-291. doi: 10.1016/j.cpt.2024.06.001. eCollection 2024 Oct.
Patients with hematological malignancies face an increased risk of developing second primary neoplasms due to various factors, including immune system compromise and chemotherapy-related effects. However, the incidence and associated risk factors in older patients remain poorly understood. This study aimed to assess the incidence, identify risk factors, and evaluate their impact on survival outcomes among older patients with hematological malignancies.
This retrospective single-center study analyzed data from 163 patients, focusing on the occurrence of second primary neoplasms. Cumulative incidence rates were calculated, and risk factor analysis was conducted using a competing risk model.
Among 124 eligible patients with a total follow-up duration of 572.57 person-years, the incidence rate of second primary neoplasms was 15.72/1000 person-years. The standardized incidence ratio (SIR) was 0.81 (95% confidence interval [CI] [0.39-1.48], = 0.518). History of radiotherapy emerged as a significant risk factor (sub-distribution hazard ratio [SHR] = 21.61 [2.81-166.14], = 0.003), whereas regular natural killer (NK) cell infusion was associated with reduced risk (SHR = 3.25 e-8 [9.81 e-9-1.08 e-7], < 0.001).
These findings underscore the importance of informing older patients with hematological malignancies about the long-term risks of second primary neoplasms. Healthcare providers should carefully weigh risk factors when formulating treatment strategies. The results are valuable for investigating the fundamental principles underlying the occurrence and progression of second primary neoplasms.
血液系统恶性肿瘤患者由于免疫系统受损和化疗相关影响等多种因素,发生第二原发性肿瘤的风险增加。然而,老年患者中的发病率及相关危险因素仍知之甚少。本研究旨在评估老年血液系统恶性肿瘤患者中第二原发性肿瘤的发病率,识别危险因素,并评估这些因素对生存结局的影响。
这项回顾性单中心研究分析了163例患者的数据,重点关注第二原发性肿瘤的发生情况。计算累积发病率,并使用竞争风险模型进行危险因素分析。
在124例符合条件的患者中,总随访时间为572.57人年,第二原发性肿瘤的发病率为15.72/1000人年。标准化发病率(SIR)为0.81(95%置信区间[CI][0.39 - 1.48],P = 0.518)。放疗史是一个显著的危险因素(亚分布风险比[SHR]=21.61[2.81 - 166.14],P = 0.003),而定期输注自然杀伤(NK)细胞与风险降低相关(SHR = 3.25 e - 8[9.81 e - 9 - 1.08 e - 7],P<0.001)。
这些发现强调了告知老年血液系统恶性肿瘤患者第二原发性肿瘤长期风险的重要性。医疗保健提供者在制定治疗策略时应仔细权衡危险因素。这些结果对于研究第二原发性肿瘤发生和进展的基本原理具有重要价值。